BMS-986260

Overview

BMS-986260, an immuno-oncology agent, is a potent, selective, and orally active TGFβR1 inhibitor ( IC 50 =1.6 nM). BMS-986260 displays exquisite selectivity for TGFβR1 over its isozyme TGFβR2 , as well as in a panel of more than 200 kinases examined. BMS-986260 inhibits TGFβ mediated nuclear translocation of pSMAD2/3 in MINK and NHLF cells lines with an IC 50 of 350 nM and 190 nM, respectively.

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TGF-β Receptor

Product Information

• Catalog No.: HY-W107024
• CAS No.: 2001559-19-7
• Molecular Formula: C18H12ClFN6O
• Molecular Weight: 382.78
• Purity: 99.95%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (6.53 mM); Clear solution
• Availability: In-stock

Source

Original product source